project update - March 13, 2025
FLAVIVACCINE project holds successful General Assembly meeting
On March 11-12, the FLAVIVACCINE consortium gathered for its biannual General Assembly meeting, bringing together partners from across the project to review progress and outline the next steps. Hosted by Consejo Superior de Investigaciones Científicas (the Spanish Research Council) , the two-day event provided an essential platform for discussing research advancements, dissemination activities, and strategic planning.
The meeting began with an overview of project developments in the past six months, presented by Julien Pompon, the project coordinator from French National Research Institute for Development (IRD). Throughout the sessions, partners shared key results from various work packages, highlighting significant progress in vaccine candidate development against multiple flaviviruses.
Specialized workshops and other activities
The second day of the meeting featured a series of specialized workshops on Intellectual Property, Key Exploitable Results and the development of the Target Product Profile for the Flavivaccine candidate.
A brief intellectual property presentation was given by attorney Lise Luciani who summarised the process of patent applications with a special focus on determination of inventorship and ownership of the invention.
The Key Exploitable Results workshop was facilitated by ICONS and helped identify the project’s most promising outcomes and their potential impact.
The Target Product Profile workshop was led by ConserV Bioscience Ltd, who highlighted the importance of considering aspects such as the indication for use and target population for the FLAVIVACCINE candidate during the developmental stages to shape the research and ensure the desired end goals are achieved.
Representatives of the Commissariat à l’Énergie Atomique et aux Énergies Alternatives, Norce Norwegian Research Centre AS, Universiteit Utrecht, the Regents of the University of California in the United States, The Geneva Foundation, and The Institut Pasteur engaged in discussions that helped to outline the objectives for the next six months, ensuring a clear roadmap for upcoming activities.
The General Assembly took place at La Real Academia Nacional de Farmacia, an institution with origins dating back to 1737. Located in Madrid, Spain, the academy is housed in a historic building that holds the highest level of protection under Spain’s Spanish State Historical Heritage. As part of the event, the hosting partners provided participants with a guided tour of this emblematic venue, offering insight into its rich history and contributions to pharmaceutical sciences.
As the FLAVIVACCINE project advances, the collaborative efforts of our partners remain crucial in developing a safe and effective vaccine against flaviviruses.
